GW501516 · GW1516 · endurobol
A substance that affects how the body uses fat (GW501516). Work on it as a medicine was stopped. No such medicine exists.
This site is for information and education only. It does not promote or encourage the use or purchase of the substances described and is not medical advice. Many are not authorised as medicines and their safety has not been established. We sell nothing and have no ties to sellers. For health decisions, consult a doctor.
Safety. In mice with a KRAS gene change, GW501516 sped up the path from early lesions to pancreatic cancer. This is an animal result, and work on it as a medicine for people has stopped. Sources: study 1.
Risk of fakes. GW501516 turned up among unapproved substances in products sold as SARMs. Only 41% of those products matched the label. Sources: study 1.
| Where | Status | Checked | |
|---|---|---|---|
| PL | No approval | The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. Source | Not yet |
| EU | No approval | The European medicines database (EMA), which covers EU and national approvals, lists no such medicine (9 October 2026). Source | Not yet |
| US | No approval | The FDA drug register has no such medicine. Source | Not yet |
Scientific papers per year 2015–2025
These are search results. A count shows how much exists, not how good the studies are. 1 Nov 2026.
Not clear. In a 2-week study with random groups of 6 people each, liver fat fell by 20%. Nobody measured body fat or weight loss. Work on it as a medicine stopped after cancer findings in mice.
What doctors, patients and companies reported to the US medicines agency (FDA), and single cases described in medical journals. A report says what happened to someone after taking the substance. It does not prove the substance caused it, and it does not say how often it happens. Reports do not change any grade.
| Most often reported | Reports |
|---|---|
| Sudden liver failure | 1 |
| Sudden psychosis | 1 |
| Brain dysfunction | 1 |
| Heavy sweating | 1 |
| Bleeding from the bottom | 1 |
| Tumour in the rectum | 1 |
| Muscle breakdown | 1 |
| More copper in urine | 1 |
Serious means the person went to hospital, their life was in danger, they were left with lasting harm, or they died. One report can list several side effects.
FDA reports come from openFDA, cases from a PubMed search. The editors have not read these cases yet. Titles stay in the original language. As of 3 Nov 2026.
A urologist who works on men's health goes through the studies on popular SARMs, MK-677 and cardarine: muscle gain, lower testosterone, the liver, cholesterol, fertility and false labels. According to the description, every SARM gets the lowest rating at the end.
| Studies | Kind of study | Who was studied | People | Duration | Dose as studied | Who paid |
|---|---|---|---|---|---|---|
| Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men. | Random groups | Healthy moderately overweight men | 18 | 2 wk | 10 mg daily | Unknown |
| Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. | Random groups | Healthy volunteers kept in hospital and inactive | 24 | 2 wk | 2.5 or 10 mg daily | Unknown |
We found these papers automatically in PubMed. The editors have not read them yet, and they do not affect any grade. Titles stay in the original language.
